As the year draws to a close, GCT team would like to take the opportunity to thank you, loyal supporters, for your continued dedication to experiencing the real difference with our high-quality clinical trials. GCT continues to expand in 2017 and has currently local offices across 10 countries in Central and Eastern Europe, Russia and India.
We always listen and appreciate your feedback and will certainly implement all the comments you made, as we believe that there is always a room for improvement.
New Studies — more opportunities to expand and strengthen GCT services list and therapeutic experience
We are proud to announce that during the past few months GCT was selected as the contractor by small and large pharma companies, governmental organizations, other CROs and biotech and medical device start-ups in connection with the research of different scales. Currently, we are conducting studies in many therapeutic areas, including surgery, cardiovascular, oncology, urology, endocrinology, ophthalmology, dermatology, diabetes, women’s health, gastroenterology,
GCT has particularly strengthened ophthalmic and medical devices portfolio bringing 6 new projects in these fields on board.
New offices are opened in Mumbai, India and Warsaw, Poland
Following the direction set last year when GCT established clinical operations in three new countries – Hungary, Czech Republic, and Slovakia, – in May 2017 the company moved further into Central Europe and opened an office in Warsaw, Poland.
Polish operations are an important addition to GCT geographical coverage, putting the company into position to provide CRO services in the majority of CEE countries and offering the access to the whole region.
The reason behind this strategic decision is continuous market demand. We have been receiving inquiries from our clients regarding capabilities in Poland throughout the years, and this year we felt it was a logical next step for company development. Our goal has always been to meet our customers’ needs and provide the best possible services within our operational and geographical expertise.
Currently GCT provides clinical research services in USA, Central and Eastern EU countries, Ukraine, Russia and India.
GCT local office in Mumbai operating under the name “GCT Pharma Research (India) Pvt Ltd” (GCT-India for short) is assisting pharmaceutical companies of all scales in performing clinical trials in India. GCT-India also supports local biopharma community willing to extend their clinical research to CEE, Russia and the U.S., thus helping them to market their products in the rest of the world. This enables GCT to expand its services to data centric and analytics solutions where India is perceived to be very strong.
GCT has appointed Dr. Umakanta Sahoo as a Managing Director, who has successfully set up the Indian entity and is in charge of the local operations. Dr Sahoo, an MBA and PhD brought his extensive experience to GCT from the pharmaceutical and CRO industries in Asia Pacific.
GCT receives a sky-scraping score by Dun & Bradstreet Rating
In 2017 GCT was rated based on the business credit information by the world’s most credible and comprehensive source of commercial data.
We scored 76 out of 80, which placed the company at the top tier in our competitive industry.
Our partners can be certain that along with the highest quality of contract research services provided by GCT worldwide there is creditworthy and significant value behind our business relationships.
GCT introduces Pharma Innovation Excellence (PHINNEX)- your partner for R&D outsourcing in Europe
This summer GCT has founded the PHINNEX consortium. The aim of this organization is to raise the awareness amongst the Biotech and Pharma Industry about the outsourcing capacity and quality capabilities offered by the region of Central and Eastern Europe.
Cost-efficient R&D outsourcing to service providers and academic institutions in Eastern and Central Europe is managed by Germany-based professionals and scientists with decades of experience in the Global Pharmaceutical Industry.
In contrast to other companies, we do not simply match the needs of Biotech and Pharma companies with Global Pharmaceutical Industry service providers’ capabilities, but on top of that we provide:
— Critical information about the most qualified Scientific Partners and Service Providers;
— Project and quality management support that ease the decision to initiate a collaboration with a previously unknown partner;
— Consulting for research projects regarding robust data quality.
PHINNEX matches your non-clinical outsourcing needs with the collaboration opportunities in the region. Professional CROs, creative academia institutes — all eager to support challenging drug research & development projects.
The combination of CEE Service Providers and Western European Management expertise allows PHINNEX to deliver unique support for your research needs.
PHINNEX is formed by Partnership for Assessment and Accreditation of Scientific Practice (PAASP), HENRICH Life Science R&D Consulting and Global Clinical Trials (GCT).
GCT Employees presenting at the international industry events
Our Legal Director, Irina Ryzhkova, M. Sc. gave several speeches this year on the important topics related to clinical trial agreements set-up, describing core terms, conditions and responsibilities of the key parties involved in Moscow and St. Petersburg forums.
In November Dr. Jeffrey Apter — one of GCT founders presented at the the Kiev Clinical Research Forum. He covered the topics of Disease Modifying Trials in Alzheimer and Overcoming the challenges of conducting CNS Studies in Ukraine and EE, sharing his invaluable experience with peers and industry leaders
Finally and most recently, Vladimir Seredyuk, MD, represented GCT Quality Assurance Department in Skolkovo Innovation Center. In his speech, Dr. Seredyuk shared his personal experience of passing the inspections of the FDA, EMA, Roszdravnadzor and the State Expert Center of the Ministry of Health of Ukraine.
GCT team contributed to the 3rd Saint-Petersburg charitable marathon aimed to raise funds for children with rare diseases
Our sporty colleagues, Anna Kuzmicheva, Natalia Krupina, Veronika Goriachikh and Alina Mitrofanenko ran 3km/5km distance past the new Saint-Petersburg stadium, where in a couple of days Conferederation Cup 2017 will start.
GCT supporters team was headed by CEO, Dr. Eugene Selivra, who promised to join the distance next year.
GCT names Tatiana Fedorova, MD, PhD the Head of Clinical Department
Dr. Fedorova has joined GCT team this July as a Head of the Clinical Department in Russia. She has a unique combination of training and higher education in medical field, research and pedagogy. She is an MD, PhD, MPH, ASSC PROF and has more than 20 years of direct clinical trial experience at the country and on a global level.
As a Head of the Clinical Department at GCT Tatiana oversees all aspects of defining the clinical operations strategy, as well as successful planning, executing, analyzing, and reporting on of company’s ongoing clinical trials in Russia ensuring that goals are met and results are delivered on time, within budget and in compliance with Good Clinical Practices, laws and regulations. Tatiana will be continuously involved into corporate training sessions, supervision of CRA and PM activities, identifying and catching any possible problems before they can have the avoidable effect on any the study.